



Nizar Krayem Design



Graphic Communications and Digital Imaging

About NKD



How Do You Pronounce His Name?

ni·**zär** **krā**·em de·**zīn**



Knee



Czar
(Tsar)



Crayon



M

Nizar

From the Arabic, meaning *glad tidings*. Named after one of the most revered contemporary poets in the Arab world, Nizar Qabbani.

Krayem

From the Arabic, meaning *generous*.

Quite literally, generously bestowing good news.

Background

Professionally designing since 1995, Nizar has worked in the corporate world and possesses a wealth of marketing experience and design expertise, spanning various industries and sectors, including: Medical Devices, High-tech Manufacturing, Education, Banking and Finance, Photonics and Optics, and Information Technology.


Specialties

Printed corporate collateral, digital design, graphic user interface and software design, interactive media, technical data sheets, brochures and catalogs, print ads and display ads, corporate identity, branding, trade show booth environments, motion graphics and video editing, website design, technical illustrations and diagrams.

Logos

Partial List

- Cytovale IntelliSep
- Sphere Financial
- Tigard Tualatin Aquatic District
- Pacific Product Guidance
- Asthma 411
- Conifer Investments
- Quoll IT
- Mission Ridge Ski and Board Resort
- Lydia Lerma Foundation



Web Site


Vave Health

vavehealth.com



Web Site

Second Sight
secondsight.com



COLTRAIN Mobile App Icon and GUI Screens

Cognition Medical



Packaging

Cytovale
IntelliSep Cartridges



Medtronic

Brochure

Imagine the benefits the Medtronic HVAD System can offer a child.

The smallest commercially available centrifugal VAD

Unmatched procedural versatility can accommodate patients of various sizes / BMI and provides surgical options for placement.

Smart, reliable data offered through Autologs and Waveforms helps inform patient management.

Excellent survival: the most recent published HVAD pediatric data from the ACTION Network demonstrated 96% survival at one year¹.

TOGETHER, LET'S REIMAGINE VAD THERAPY

More lives touched in the most beautiful way.

For over a decade, the HVAD System has been implanted in more than 18,000 patients – more than 400 of whom were children. Now, with the singular lead reduction, pediatric surgeons have an approved life-saving HVAD technology for their pediatric heart patients.²

STILL THE SMALLEST COMMERCIALLY AVAILABLE CENTRIFUGAL VAD

The Same Medtronic Quality You've Come to Depend On

30% smaller than other devices³

20% lighter than other devices³

36% less displaced volume²

"The Medtronic HVAD [Pump] has been a workhorse device for us. It has been a really good, durable device that can rehabilitate a child well."
Dr. Umar Boston
Lebonheur Children's Hospital, Memphis

Discover HVAD, Enhanced

In partnership with you, we continue to build on this trusted and proven technology to deliver a series of enhancements designed to improve outcomes, reduce adverse events and deliver peace of mind with every implant.

Carbonthane Driveline
Offering greater flexibility and increased durability, compared to the previous Polyurethane driveline, the Carbonthane driveline is designed with a new pump data faster and strain relief onto the HVAD™ Pump.

Quick Connect
Designed to provide secure, reliable connection during surgical assembly, Quick Connect includes three product enhancements designed to improve assembly of the outflow graft and ease of handling to improve driveline management.

Smart Technology
Autologs 1.3 is the latest update to the Medtronic advanced device management service, and enables VAD Coordinators to access important pump data faster and with greater convenience.

Learn more about HVAD enhancements by visiting www.medtronic.com/DiscoverHVAD

MOST WIDELY STUDIED CENTRIFUGAL LVAD

With more than a decade of clinical evidence in adults and multicenter worldwide experience with pediatric patients beginning in 2009, the Medtronic HVAD System is the most widely studied LVAD across both patient populations.^{1,2}

Recent Analysis of HVAD in Pediatric Patients Demonstrated 96% Survival at One Year¹

	1 year	2 year	3 year	4 year
Transplanted	100%	100%	100%	100%
Mean survival	96%	96%	96%	96%
Overall	96%	96%	96%	96%
Overall off device	96%	96%	96%	96%

A study of 50 pediatric patients implanted with HVAD at 16 ACTION centers between April 1, 2009 and April 13, 2010, demonstrated 96% survival at 1 year. The most frequent AEs were bleeding (7/50) and infection (2/49). www.sciencedirect.com

SURVIVAL IN CHILDREN ENCOURAGING, COMPARABLE TO YOUNG ADULTS

A separate study of 192 children and 247 young adult Medtronic HVAD patients showed that overall survival was not statistically different between the two groups, and there was no increased mortality in children who weighed < 20 kg.

Worldwide Multicenter Pediatric Experience with the HVAD System

A study of 205 patients from 34 centers in 12 countries implanted between 2009 and 2010 revealed use of the Medtronic HVAD System in the pediatric population is associated with a low mortality. A majority of patients were supported to transplant by one year post implant, and the results appear to be independent of geographic location.³

Discharged
96% (n=195) home on device (n=195)

Admissions
Median duration of hospital stay = 43 days

Support
Median duration of VAD support = 4.5 years (range 1 to 6 years)

Survival
Survival at 1 month = 100% at 1 year = 96%

"The Medtronic VAD is an excellent example of cutting-edge technology that saved Tyler's life. The VAD transformed my tiny, fragile baby into a healthy, happy, and active boy. Tyler was able to gain weight, grow taller and stronger, and even attend school. Our family will be forever grateful... for helping him become a transplant candidate."
Danielle, Tyler's Mother

"Tyler transplanted after 12 months on support with the HVAD System"

IMAGINE THE LIVES YOU'LL TOUCH

Lucas, transplanted after 12 months on support with the HVAD System

Together, let's reimagine VAD therapy.

OUR COMMITMENT

Medtronic is committed to advancing VAD therapy which aligns with our mission to alleviate pain, restore health, and extend life. We are proud our life-saving HVAD technology is now approved for pediatric heart patients, and we look forward to partnering with pediatric centers to continue to learn and imagine new and innovative ways to help children suffering from heart disease.

Let's take healthcare further, together.

"The HVAD was life-changing. Lucas went into the hospital on Thanksgiving. With the HVAD he was home for Christmas. He returned to school in the spring and resumed his activities. He was in good physical condition and happily living life while we waited for transplant. Truly a miracle."
Sean, Mother of Lucas

"The HVAD was truly a godsend for me and my family. It was a great bridge to transplant. By increasing my cardiac output, it allowed me to build up my strength, to eat without feeling nauseous, and have a higher quality of life. I am so thankful for the HVAD and truly don't know if I would've made it to transplant without it."
Kerlee, Mother of Kerlee

DARE THEM TO IMAGINE AGAIN

HVAD™ System for Pediatric Patients¹

Our patient population just got more adorable

Imagine the benefits the Medtronic HVAD System can offer a child.

STILL THE SMALLEST COMMERCIALLY AVAILABLE CENTRIFUGAL VAD

The Same Medtronic Quality You've Come to Depend On

30% smaller than other devices³

20% lighter than other devices³

36% less displaced volume²

"The Medtronic HVAD [Pump] has been a workhorse device for us. It has been a really good, durable device that can rehabilitate a child well."
Dr. Umar Boston
Lebonheur Children's Hospital, Memphis

Discover HVAD, Enhanced

In partnership with you, we continue to build on this trusted and proven technology to deliver a series of enhancements designed to improve outcomes, reduce adverse events and deliver peace of mind with every implant.

Carbonthane Driveline
Offering greater flexibility and increased durability, compared to the previous Polyurethane driveline, the Carbonthane driveline is designed with a new pump data faster and strain relief onto the HVAD™ Pump.

Quick Connect
Designed to provide secure, reliable connection during surgical assembly, Quick Connect includes three product enhancements designed to improve assembly of the outflow graft and ease of handling to improve driveline management.

Smart Technology
Autologs 1.3 is the latest update to the Medtronic advanced device management service, and enables VAD Coordinators to access important pump data faster and with greater convenience.

Learn more about HVAD enhancements by visiting www.medtronic.com/DiscoverHVAD

Medtronic

Full-Page Print Ads

DARE TO IMAGINE AGAIN

The Medtronic HVAD™ SYSTEM
Now Approved for Pediatrics¹

With more than a decade of clinical evidence in adults and multicenter worldwide experience with pediatric patients beginning in 2009, the HVAD System is the most widely studied LVAD across both patient populations.¹,²

So they can imagine again.

¹ Medtronic data on file.
² Conway J, et al. Worldwide Experience Of A Durable Centrifugal Flow Pump in Pediatric Patients. Semin Thorac Cardiovasc Surg. 2018;30(3):327-335.

Brief Statement
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Indications
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Contraindications
The HVAD System is contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Warnings and Precautions
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Potential Complications
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Caution: Contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.



"The HVAD was truly a godsend for me and my family. It was a great bridge to transplant. By increasing my cardiac output, it allowed me to build up my strength, to eat without feeling nauseous, and have a higher quality of life. I am so thankful for the HVAD and truly don't know if I would've made it to transplant without it."

Aimee, 12 months on support with the HVAD System before transplant

To learn more, visit www.medtronic.com/hvad

Medtronic
Further. Together.

DARE TO IMAGINE AGAIN

The Medtronic HVAD™ SYSTEM
Now Approved for Pediatrics¹

Most Widely Studied LVAD
With more than a decade of clinical evidence in adults and multicenter worldwide experience with pediatric patients beginning in 2009, the HVAD System is the most widely studied LVAD across both patient populations.¹,²

So they can imagine again.

¹ Medtronic data on file.
² Conway J, et al. Worldwide Experience Of A Durable Centrifugal Flow Pump in Pediatric Patients. Semin Thorac Cardiovasc Surg. 2018;30(3):327-335.

Brief Statement
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Indications
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Contraindications
The HVAD System is contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Warnings and Precautions
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Potential Complications
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Caution: Contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.



"The HVAD was life-changing. Lucas went into the hospital on Thanksgiving. With the HVAD, he was home for Christmas. He returned to school in the spring and resumed his usual activities. He was in good physical condition and happy living life while we waited for transplant. Truly amazing."

Sarah, mother of Lucas, 11 months on support with the HVAD System before transplant

To learn more, visit www.medtronic.com/hvad

Medtronic
Further. Together.

DARE TO IMAGINE AGAIN

The Medtronic HVAD™ System
Now Approved for Pediatrics

With more than a decade of clinical evidence in adults and multicenter worldwide experience with pediatric patients beginning in 2009, the HVAD System is the most widely studied LVAD across both patient populations.¹,²

So they can imagine again.

¹ Medtronic data on file.
² Conway J, et al. Worldwide Experience Of A Durable Centrifugal Flow Pump in Pediatric Patients. Semin Thorac Cardiovasc Surg. 2018;30(3):327-335.

Brief Statement
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Indications
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Contraindications
The HVAD System is contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Warnings and Precautions
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Potential Complications
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Caution: Contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.



"Here's Kaylee transplanted. Without the HVAD going home again, would never have been an option. She wouldn't have survived until transplant."

Susan, mother of Kaylee, 30 months on support with the HVAD System before transplant

To learn more, visit www.medtronic.com/hvad

Medtronic
Further. Together.

DARE TO IMAGINE AGAIN

The Medtronic HVAD™ System
Now Approved for Pediatrics

Most Widely Studied LVAD
With more than a decade of clinical evidence in adults and multicenter worldwide experience with pediatric patients beginning in 2009, the HVAD System is the most widely studied LVAD across both patient populations.¹,²

So they can imagine again.

¹ Medtronic data on file.
² Conway J, et al. Worldwide Experience Of A Durable Centrifugal Flow Pump in Pediatric Patients. Semin Thorac Cardiovasc Surg. 2018;30(3):327-335.

Brief Statement
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Indications
The Medtronic HVAD System is indicated for hemodynamic support in adult and pediatric patients with end-stage heart failure who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Contraindications
The HVAD System is contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Warnings and Precautions
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Potential Complications
The HVAD System is a mechanical device and is subject to the same risks as other mechanical devices. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.

Caution: Contraindicated in patients who are not candidates for heart transplantation or who are awaiting heart transplantation. The HVAD System is not intended for use as a bridge to heart transplantation or as a destination therapy for patients who are not candidates for heart transplantation.



"The Medtronic VAD is an excellent example of cutting-edge technology that saved Tyler's life. The VAD transformed my dying child into a happy and silly little boy. Tyler was able to gain weight, grow taller and stronger, and even attend school. Our family will be forever grateful...for helping him become a transplant candidate."

Danielle, mother of Tyler, 18 months on support with the HVAD System before transplant

To learn more, visit www.medtronic.com/hvad.

Medtronic
Further. Together.

Ceterix Orthopaedics



IceCure Medical
Flyers & Trifold Brochure

Corporate Collateral

Predictable Treatment of Fibroadenoma in the Office

The procedure utilizes cryoablation for destruction of tumors in situ. Building on the established clinical efficacy of cryoablation, IceCure Medical developed a system that is optimized to efficiently treat symptomatic fibroadenomas in the office with ultrasound guidance. The advanced cryoablation probe design is customized to match the size and shape of the targeted fibroadenoma.

IceSense 3 Delivers the Promise of Rapid, Office Cryoablation for Fibroadenomas

Fast, Easy, Comfortable Procedure

- Simple, ultrasound-guided procedure treated in less than 5 minutes
- Office-based cryoablation is comfortable for patients
- Patients report high satisfaction from treatment and results
- Ablation is applied to the targeted fibroadenoma, while proximal probe and handle kept warm
- Effective, durable procedure for treating fibroadenomas

IceCure Reimbursement For Healthcare

IceCure has contracted a reimbursement specialist company, Argenta Advisors, to assist with the IceSense3 cryoablation procedure and your staff with the reimbursement.

Let the Support Line Help

- Address coding and coverage inquiries
- Assist with policy research for major breast fibroadenoma, and is available and your staff with the reimbursement
- Guide and navigate you through the procedure
- Identify payer-specific appeals process
- Access tools, resources and support
- Facilitate communication with payers

What Healthcare Professionals Should Do

- Request prior authorization before procedure
- Complete and sign the Patient Referral Form
- Complete the patient's insurance card (front and back)
- Ensure the patient's medical information documenting medical necessity for the surgical procedure. Include copy of denial letter, if applicable
- Obtain copy of patient's insurance card (front and back)
- Gather the patient's medical information documenting medical necessity and/or appeals letter
- Review and sign the prior authorization letter in the patient's record
- Keep copies of all forms/supporting documentation in the patient's record
- Submit package to payer within the required timeframe

* Use of the Reimbursement Support Line does not guarantee insurance coverage. The time allowed for submitting appeals varies by payer, so submit the claim claim first.

You have a Fibroadenoma What Are Your Options?

IceSense3 IceCure

What is a Fibroadenoma?

Fibroadenomas are the most common type of breast tumor (lump). They are solid (not fluid-filled) masses, have clearly defined edges and are typically round or oval in shape. Fibroadenomas are benign, which means they are not cancerous, and do not turn into cancer. They may increase in size with time, particularly with hormonal changes.

What are Common Symptoms?

Fibroadenomas may be palpable (able to be felt) in the breast. While some remain unchanged for many years, they may grow to a size larger than a golf ball over time. Some women find these lumps or masses uncomfortable and bothersome, and may have associated pain or tenderness. In some cases, fibroadenomas can physically deform the breast. The level of anxiety with these breast masses is personal.

How is a Fibroadenoma Detected?

Fibroadenomas are usually found during a breast self-examination, or a clinical examination (breast exam performed by a physician). Further studies may be done: ultrasound, mammography, or other imaging such as MRI. While fibroadenomas tend to have a typical appearance on physical exam and imaging, the diagnosis must be confirmed – no imaging study can fully ensure that a lump is indeed benign.

What Are My Options?

Watchful Waiting

You may choose to observe your fibroadenoma over time, and feel your breast for changes. Your doctor may request follow-up visits every 6-12 months and ultrasound or other imaging to check for any changes in the lump. If the fibroadenoma enlarges or becomes uncomfortable, your doctor would recommend a treatment option.

Surgery

Fibroadenomas can be removed surgically. This procedure is performed in the operating room and includes surgically removing the fibroadenoma and suturing (stitching) the incision closed. Depending on the size of the fibroadenoma and the location in the breast, healing may result in an indentation or change in the shape and size of the breast. In addition, the size of the scar on the skin will vary depending on the size of the fibroadenoma.

Office-Based Cryoablation

Cryoablation is an FDA-approved treatment for destroying fibroadenomas, and is an alternative to open surgery. It is the use of extreme cold technology to completely destroy tissue. Cryoablation has been used for decades to destroy benign and cancerous tumors in prostate, liver and other organs. The technology and procedure has been optimized for breast fibroadenomas.

Frequently Asked Questions

- 1 Is PROPEL clinically proven?**
PROPEL's safety and efficacy is backed by the highest level of clinical evidence.¹ Over 150,000 people have been treated with PROPEL.
- 2 Will I feel PROPEL in my sinus?**
PROPEL is lightweight and usually cannot be felt once in place.
- 3 What should I do after the procedure?**
Always follow your doctor's instructions. Frequent saline irrigations are important for post-surgical healing.

Hear What Others Are Saying at [MySinusitis.com/stories](https://www.mysinusitis.com/stories)



"I could breathe. There was no stuffiness. The recovery was just a few days." – Tammy

"I haven't had a sinus infection since I had the procedure done. I breathe better. I'm able to exercise more." – Michael

Results vary. See back cover for information on benefits and risks.



1. Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2. Forwith KD, Chandra RK, Yun PT, Miller SK, Jampel HD. Laryngoscope. 2011;121:2477.

The PROPEL sinus implants are intended for use following sinus surgery to maintain the sinus openings and to locally deliver a drug to the sinuses: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening and PROPEL Contour for use in the frontal and maxillary sinus openings. The products are intended for use in patients ≥18 years of age. These products are not intended for people who are allergic to the drug (mometasone furoate) or to certain polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, movement of the implant (within or out of the sinus), possible side effects of the drug, infection, and nose bleed. For more information on the risks and benefits of PROPEL sinus implants, please talk to your doctor. The FDA approved labeling can be found at www.intersectent.com, Rx only.

©2017 Intersect ENT, Inc. INTERSECT ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

MPM 00265 Rev B

Chronic Sinusitis Relief

THERE'S HOPE. 



PROPEL[®]

MOMETASONE FUROATE SINUS STENT

Shown to improve the results of sinus surgery.¹

Don't Just Treat the Symptoms. Treat the Source.

Sinus surgery with PROPEL is clinically proven to provide relief by targeting **inflammation**², the primary characteristic of chronic sinusitis.



PROPEL sinus stent



1 OPENS

After sinus surgery, PROPEL is placed to help prop open the sinus.



2 DELIVERS

PROPEL delivers medicine directly to the sinus to help reduce inflammation that could block the opening.



3 DISSOLVES

As the sinus heals open, PROPEL is designed to dissolve within 45 days.

Sinus Surgery Has Advanced

If you and your physician have discussed sinus surgery, be assured that it is easier and less invasive than ever before.



Small instruments are introduced through the nostrils to open sinuses blocked by inflammation.



Uncomfortable gauze packing is a thing of the past.




PROPEL is placed in the sinus after surgery to promote healing and reduce the need for additional procedures.

Learn More


Ask your doctor for more details about sinus surgery with the PROPEL sinus stent.

To learn more about sinusitis, treatment options, and PROPEL, visit [MySinusitis.com](https://www.mysinusitis.com)

PROPEL[®]



Concentric Medical
Bifold and Trifold Brochures



Data Sheets

Life Scope® G5 Bedside Monitor
Premium, All-in-One Monitor

The Life Scope G5 is a bedside monitor available with 12.1" or 15.6" display designed for high to mid-level acuity settings where clinicians need an all-in-one system with quick access to multiple configurations and trend analysis.

- More Data**
 - Includes 12-lead ECG capabilities for clear visualization and easier interpretation of heart conditions
 - Offers a complete data record, including multi-waveform, multi-parameter full disclosure
 - Combines vital signs patient monitoring and advanced neurology monitoring
- More Insight**
 - Aids clinicians in determining treatment approaches with drug, hemodynamic and pulmonary calculations
 - Provides deep understanding into what is happening in a patient's heart with advanced atrial fibrillation algorithm, and enhanced review capability ST analysis and recall
- More Efficiency**
 - Improve workflow with seamless one admit one discharge across the entire Nihon Kohden Patient Monitoring System
 - Employs intuitive user interface for quick access to data and functions
 - Reduces alarm fatigue using escalation latching and delayed alarm functionality

Specifications

Display	Straight-line Resolution	Characteristics	Number of Traces	Waveforms	Screen Speed	Numerical Data Display
12.1"	1280 x 800	16M colors	12	ECG, BP, SpO2, Temp, Respiration, Neurology, etc.	Fast	Yes
15.6"	1920 x 1080	16M colors	12	ECG, BP, SpO2, Temp, Respiration, Neurology, etc.	Fast	Yes

NIHON KOHDEN
www.nihonkohden.com

For more information, please contact us at 1-800-725-2263 or visit us online at www.nihonkohden.com

NK-HiQ™

Wireless Server Extension

Smart. Safe. Secure.

Patient Monitoring Reinvented

- Unlocks the power of WiFi in a smart and secure manner to provide breakthrough monitoring using the management platform of the NK-HiQ™ Wireless Server Extension.
- Enables expansion of ambulatory monitoring throughout the hospital, a critical factor that may decrease outcomes.
- Offers complete and continuous data collection even during transport, which can be one of the most dangerous times for critically ill patients.
- Leverages 802.11 infrastructure, vastly reducing the cost of deployment.

True WiFi for Continuous Monitoring

- Uses shared hospital WiFi or dedicated WiFi networks without sacrificing existing bandwidth.
- Supports diverse WiFi requirements, including deployment on a shared SSID.
- Protects data during periods of WiFi coverage loss with its seamless backup function.
- Supports the latest wireless security protocols, including 802.1X and WPA2 Enterprise with AES encryption and EAP authentication.
- Ensures security through Windows® server security patches validated on a monthly basis.
- Provides seamless integration with the hospital's enterprise system.

Monitoring Accessibility

- Automatically transfers 12-lead ECGs to Life Scope® bedside monitors using NK-HiQ™ ECG Server Extension.
- Provides diagnostic-quality 12-lead ECGs.
- Utilizes Datamedical™ translation to transfer 12-lead ECGs to be sent to most management systems.

Eliminating Alarm Fatigue

- Assists in identifying and eliminating unnecessary alarm events to focus on the most critical patient safety issues.
- Provides meaningful and actionable data to the clinical organization.

Becoming a Centralized Monitoring System

- The AWARE system integrates with all major hospital systems and devices.
- The system can be deployed in a variety of ways.

Nihon Kohden

NK-HiQ is a trademark of Nihon Kohden Corporation.
Datamedical is a trademark of Datamedical LLC.
Life Scope is a registered trademark of Nihon Kohden Corporation.

AWARE and Patient Monitoring for Better Healthcare are registered trademarks.

Data Sheets

Acclarent


A Johnson & Johnson Company

Corporate Collateral



One-Sheet

Impulse Dynamics



Picarro

Bifold Brochures and Data Sheets

Corporate Collateral



Spectra-Physics

Full-Page Print Ads

DIVE DEEP INTO
the power of InSight

As the leader in Ultrafast, Spectra-Physics® continually breaks barriers, taking laser technology and capabilities where no one has gone before. The new InSight DS+ delivers the highest peak power at the right wavelengths, perfect for deep, in vivo imaging in neuroscience, cancer research, and immunology. Discover the power and flexibility of InSight DS+ to perform simultaneous imaging of all commonly used fluorescent proteins, SHG and THG imaging of endogenous structural proteins, CARS and SRS imaging and much more.

Harness the power to give your research deeper InSight.

- Broadest tuning range: 680 nm to 1300 nm for deepest imaging
- Short pulse width and highest peak power for maximum fluorescence
- Dual wavelength output at 1041 nm for simultaneous two-photon imaging, SHG, photo-stimulation, CARS and SRS
- Integrated patented DeepSee to deliver short pulses to the sample

Left: Live mouse barrel cortex. Gabriel Jones & Stefan Heide, Max Planck Institute of Neurobiology and Mental Health.
Right: Live ultrashort-pulse excitation enables live imaging. Spectra-Physics, Institute for Neurobiology, Albert-Ludwig-University.

#1 Family of Ultrafast Lasers for Bio-Imaging
InSight® DS+™ | Mai-Tai® DeepSee™ | HighQ-2™ | femtoTrain™

Spectra-Physics
A Newport Company

For more information on the InSight DS+, visit www.spectra-physics.com/InSight-DS+ or call 1-800-775-5273.

illuminate
YOUR PATHWAY TO DISCOVERY

Molecular 3D image of Mouse Brain Cortex
Yusuke Okawa, Translational Research Center, Osaka University (Japan)
March Inman, Department of Molecular Medicine for Regenerative, Osaka University Graduate School of Medicine (Japan)

Left: Mai-Tai DeepSee laser system. Right: InSight DeepSee laser system.

Our family of ultrafast lasers takes your research to new depths. Achieve deep in vivo imaging with InSight DeepSee's straightforward access to long infrared excitation wavelengths. Generate bright, crisp images enabled by our lasers' short pulse widths and built-in dispersion compensation to achieve the highest multiphoton imaging contrast.

Spectra-Physics
A Newport Corporation Brand

For more information, visit www.newport.com/discovery or call 1-800-775-5273.

unrivaled performance
ENABLING NEW DIMENSIONS
IN ADDITIVE MANUFACTURING

How do you stay unrivaled? By continually challenging the norm, pushing boundaries and breaking barriers. Spectra-Physics has been on the forefront of additive manufacturing since its inception. Our leadership in UV and innovative laser technology propels the industry forward. Explorer® XP shattered convention as the industry's first compact *It's in the Box™* laser delivering exemplary performance and power. And now, Explorer® One™ delivers an even smaller footprint, truly putting power in the palm of your hand. **Sometimes the smallest advances have the largest impact.**

Explorer family: industry's smallest UV lasers

- *It's in the Box* integrated laser head and electronics
- >7x smaller than any competitive laser
- Air cooled
- Short pulse width, high peak power
- Superior beam quality

Top: Explorer XP designed for high power for 3D printing. Bottom: Explorer One offers a wide range of printing options. Left: Materials use the Spectra-Physics Explorer in their manufacturing build process to create custom end user products.

Spectra-Physics
A Newport Company

For more information on our #1 in UV line of lasers, visit www.spectra-physics.com/uv-lasers

shattering the UV barrier
A NEW PARADIGM FOR UV CAPABILITY,
COST-PERFORMANCE, AND RELIABILITY

Quasar® 355-60:
Groundbreaking UV Capability

- >60 W and >300 µJ/pulse
- 0 to 3.5 MHz repetition rates
- <2 to >100 ns adjustable pulse width
- TimeShift™ programmable pulse profiles
- High volume production for 24/7 applications

Talon™: Disruptive UV Cost-Performance

- >15 W and >300 µJ/pulse
- Lowest cost of ownership with no compromise in features or reliability
- Enabling micromachining with high throughput and lowest cost
- Rapidly ramping volume production


Spectra-Physics
A Newport Company

For more information on our #1 in UV line of lasers, visit www.spectra-physics.com/uv-lasers or call 1-800-775-5273.

Precision Photonics

Full-Page Print Ads

Two Innovative Products,





Broadband
High Power
High Extinction
Epoxy Free
Low TWE

LOW
DISPERSION

One Common Bond

In order to accommodate your specific needs, PPC has developed two new fused silica polarizers that utilize our CAD® bonding and IBS coating technologies. These cubes are available from stock, and work at many wavelengths so you don't have to put up with expensive custom coatings or long lead times. Email us your requirements today!



 precisionphotonics www.precisionphotonics.com | 303-444-9948 | sales@precisionphotonics.com

Impossible ideas made possible.



Who's turning your ideas into reality?

To learn more about PPC's epoxy-free bonding, ion-beam-sputtered coatings and how we make the impossible possible, visit us at www.precisionphotonics.com





 precisionphotonics www.precisionphotonics.com | 303-444-9948 | sales@precisionphotonics.com

Tight tolerances, epoxy-free and a short leadtime...

...how about something challenging?

You've got tough specs, a short deadline and a boss breathing down your neck. You need the part and you need it done right... the first time. That's where we come in. Call or email us your requirements to find out how we make the impossible possible!



 precisionphotonics www.precisionphotonics.com | 303-444-9948 | sales@precisionphotonics.com

Have Your Cake and Eat it Too!



You don't have to sacrifice bandwidth or extinction ratio to get low dispersion

Until now, there's been no way to polarize femtosecond laser systems without sacrificing wavefront, bandwidth or dispersion control. PPC's new PBS-GVD prism polarizer does it all!

Features: high extinction ratio, high damage threshold, epoxy-free, low dispersion materials, no refraction, broad bandwidth (700-1100 nm), exceptional wavefront quality.



 precisionphotonics www.precisionphotonics.com | 303-444-9948 | sales@precisionphotonics.com


Catalog

Precision Photonics






Posters

Precision Photonics



Oregon Open

Squash Tournament Posters



Rollup Banner Stands


Daylight Solutions



Environmental

- ATMOSPHERIC MONITORING AND NETWORKS
- AMBIENT AIR QUALITY
- STACK EMISSIONS MONITORING
- MARINE SHIP EMISSIONS MONITORING
- VEHICLE EMISSIONS MONITORING
- AND MORE...


DAYLIGHT SOLUTIONS



Medical

- BREATH DIAGNOSTICS
- GLUCOSE MONITORING
- HOSPITAL AIR QUALITY MONITORING
- ANESTHESIA MONITORING
- BREATH ALCOHOL DETECTION
- AND MORE...


DAYLIGHT SOLUTIONS



Defense

- IRCM
- STAND-OFF EXPLOSIVE DETECTION
- CHEMICAL AGENT DETECTION
- CONTAINER SCREENING
- MASS TRANSIT SCREENING
- THERMAL ILLUMINATION
- AIMING
- AND MORE...


DAYLIGHT SOLUTIONS



Scientific

- MOLECULAR SPECTROSCOPY
- MULTI-SPECIES DETECTION
- COMBUSTION DIAGNOSTICS
- OPO SEEDING
- MID-IR ILLUMINATION
- AND MORE...

DAYLIGHT SOLUTIONS



Industrial


- LEAK DETECTION
- PERSONAL EXPOSURE MONITORING
- NATURAL GAS CONTAMINANT MONITORING
- PETROCHEMICAL PROCESS MONITORING
- PHARMACEUTICAL PROCESS/QUALITY CONTROL
- AND MORE...

DAYLIGHT SOLUTIONS

Rollup Banner Stands

Concentric Medical

outcomes determine winners



Outcomes Compared
proportion of patients with mRS score of ≤ 2 at 90 days

Group	Penumbra	Multi MERCI	Multi MERCI Subset*
All Patients	25% (31/125)	36% (53/160)	42% (46/109)
Revascularized Patients*	29% (30/102)	49% (25/51)	53% (41/77)

*p=0.040** p=0.0054* p=0.0047* p=0.0019*

■ Penumbra ■ Multi MERCI ■ Multi MERCI Subset*

*Data are percentages (n/N). **p < 0.05 by Fisher's exact test. *p < 0.05 by chi-square test.

merc i
RETRIEVAL SYSTEM™

Ask a Concentric Representative For More Information

our most efficient retrievers yet



merc i
RETRIEVAL SYSTEM™

Introducing The New
merc i® V-Series

Ask a Concentric Representative For More Information

Rollup Banner Stands

Ceterix Orthopaedics



CETERIX[®]
ORTHOPAEDICS

Revolutionizing Meniscus Repairs

with every stitch

Expanded Meniscus Repair Options
Provides a new option to address vertical, horizontal, radial and root tears.

Circumferential Compression Stitch
Creates a more anatomic repair by uniformly compressing both the tibial and femoral sides of the tear.

All-Inside, All-Suture Implant-Based Repairs
Replaceable cartridge enables suture placement in a single insertion for rapid repairs.

Intra-articular Needle
Designed to limit risks to neurovascular structures and allow stitching at the popliteal hiatus.

Refer to the Instructions for Use for device-specific indications, adverse effects, warnings and precautions.



REPLACEMENT CARTRIDGE
with pre-loaded suture implant for rapid repairs.



Now 510K Cleared

LOW PROFILE:
1.6 mm upper jaw to access more tears.

Extendable lower jaw slides under the meniscus for PRECISE STITCH PLACEMENT

Needle and suture pass vertically (from tibial to femoral) to enable the CIRCUMFERENTIAL COMPRESSION STITCH

Refer to the Instructions for Use for device-specific indications, adverse effects, warnings and precautions.



Circumferential Compression Stitch



Complex Tears Made Simple



Designed to Limit Risks to Neurovascular Structures



NovoStitch[™]
meniscal suture passer

- All inside
- Suture only
- Tibial to femoral suture passing
- Suture pattern flexibility
- Aims to keep needle intra-articular

Tradeshow Graphics

EBR Systems

10×10 Back Wall



Tradeshow Graphics

Aegea Medical

20×10 Back Wall



Tradeshow Graphics

Second Sight

10×10 Back Wall



Tradeshow Graphics

M Squared Lasers

10×10 Back Wall



Tradeshow Graphics

Ceterix Orthopaedics

10×10 Back Wall



Clients

Partial List

- | | | |
|----------------------|---------------------|-------------------------------|
| Acclarent | Impulse Dynamics | Optimedica |
| Aegea Medical | Intersect 360 | Picarro |
| Ardian | Intersect ENT | Precision Photonics |
| Arstasis | Kalera Medical | Procept BioRobotics |
| Asahi Intecc | Los Gatos Research | Qnovo |
| Augmedics | M Squared Lasers | Route 92 Medical |
| Ceterix Orthopaedics | Medtronic | Second Sight Medical Products |
| Cognition Med | Miramar Labs | Spectra-Physics |
| Concentric Medical | Moximed | Stryker Corporation |
| Covidien | NeoTract | The Detection Group |
| Cytovale | Nevro | Topcon Medical Systems |
| Daylight Solutions | New Focus | UNT Health Science Center |
| EBR Systems | Newport Corporation | Vave Health |
| IceCure Medical | Nihon Kohden | |

Thank You

CONTACT

 503-290-4465

 nizar@nizarkrayem.com

CONNECT

 [linkedin.com/in/nizarkrayem](https://www.linkedin.com/in/nizarkrayem)

COLLABORATE

 Let's Work Together

